secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0000944809-23-000015
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO subsidiary ModeX licenses EBV vaccine to Merck for $50M upfront, up to $872.5M milestones
--------------------------------------------------------------------------------

- ModeX grants Merck exclusive worldwide license for MDX-2201, a preclinical nanoparticle vaccine targeting EBV.
- OPKO receives $50M upfront; eligible for up to $872.5M in development and commercial milestones.
- Tiered royalties from high single digits to low double digits on global sales of the vaccine product.
- Joint research program until IND filing; Merck to lead clinical development and commercialization thereafter.
- A portion of payments may be payable to Sanofi under ModeX's prior in-license agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000094480923000015/0000944809-23-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000094480923000015/opk-20230308.htm
  HTML page:      https://secwatch.observer/filing/0000944809-23-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer